Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 9/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841213 | 0.87 | EPHX2 (0.42) | EPHX2POLBHSD17B10SIGMAR1HRH3 | |
| SCHEMBL22208127 | 0.84 | POLB (0.46) | EPHX2POLBHSD17B10ACKR3SIGMAR1 | |
| SCHEMBL6123413 | 0.83 | POLB (0.38) | EPHX2POLBHSD17B10PARP1ACKR3 | |
| SCHEMBL2772737 | 0.82 | EPHX2 (0.51) | EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL23573288 | 0.80 | POLB (0.56) | POLBHSD17B10ACKR3SIGMAR1HRH3 | |
| SCHEMBL3369574 | 0.80 | POLB (0.51) | POLBHSD17B10CYP2D6ACKR3SIGMAR1 | |
| SCHEMBL4746146 | 0.78 | EPHX2 (0.36) | EPHX2POLBHSD17B10HSP90AA1ACKR3 | |
| SCHEMBL12544593 | 0.78 | CTSK (0.48) | EPHX2SIGMAR1 | |
| SCHEMBL14760896 | 0.76 | CHRM2 (0.48) | EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL21853654 | 0.76 | HPGDS (0.44) | EPHX2POLBHSD17B10SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454236-B1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-09-04 | — | — | EP | disclosed |
| WO-2015161011-A1 | BENZAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-8877944-B2 | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-20120245142-A1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-09-27 | — | — | US | disclosed |
| WO-2011006794-A9 | 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245142-A1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | EPHX2 2213/4885POLB 118/4885HSD17B10 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.